Skip to main content


Table 1 Patient attrition for antiretroviral-naïve HIV+ patients initiating atazanavir-containing vs. atazanavir-free regimens

From: Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study

Criterion Commercial Database Medicaid Database
Patients with ≥1 prescription for an ARV medicationa between 1/1/2007 and 12/31/2013 (first claim = index date) 98,672 31,806
AND age 18–64 at index date 97,911 29,782
AND continuous enrollment for ≥6 months prior to index date 36,942 13,197
AND no eligibility for Medicare 36,942 13,181
AND no claims for ARV medications prior to index dateb 26,958 7,731
AND ≥1 claim with an HIV diagnosis prior to index dateb 22,285 7,185
AND no CV eventc in the 6 months prior to index date 22,211 7,136
Final Study Population 22,211 7,136
 Initiated ATV-containing regimen 2,437 1,505
 Initiated ATV-free regimen 19,774 5,631
 Initiated PI-free regimen 16,131 3,931
 Initiated other PI-containing regimen 3,643 1,700
 Initiated DRV-containing regimen 1,551 527
  1. ARV antiretroviral, ATV atazanavir, DRV darunavir, CV cardiovascular, PI protease inhibitor
  2. aARV medications included non-nucleoside reverse transcriptase inhibitors, protease inhibitors (excluding ritonavir), integrase inhibitors, fusion inhibitors and CCR5 antagonists. bUsing all data prior to index date starting with 2004. cMyocardial infarction, stroke, percutaneous coronary intervention, or coronary artery bypass graft